KALA PHARMACEUTICALS INC's ticker is KALA and the CUSIP is 483119103. A total of 89 filers reported holding KALA PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 5.28 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $53,000 | -70.6% | 38,156 | -74.3% | 0.00% | – |
| Q4 2021 | $180,000 | -42.1% | 148,421 | +25.1% | 0.00% | – |
| Q3 2021 | $311,000 | -66.5% | 118,669 | -32.2% | 0.00% | -100.0% |
| Q2 2021 | $928,000 | -3.7% | 175,118 | +22.5% | 0.00% | 0.0% |
| Q1 2021 | $964,000 | -4.6% | 142,999 | -4.1% | 0.00% | 0.0% |
| Q4 2020 | $1,011,000 | -9.5% | 149,053 | +0.1% | 0.00% | 0.0% |
| Q3 2020 | $1,117,000 | -50.8% | 148,898 | -31.0% | 0.00% | -50.0% |
| Q2 2020 | $2,270,000 | +64.5% | 215,943 | +37.6% | 0.00% | +100.0% |
| Q1 2020 | $1,380,000 | +168.0% | 156,985 | +12.6% | 0.00% | – |
| Q4 2019 | $515,000 | +153.7% | 139,441 | +160.9% | 0.00% | – |
| Q3 2019 | $203,000 | -19.8% | 53,444 | +34.6% | 0.00% | – |
| Q2 2019 | $253,000 | -9.6% | 39,692 | +17.1% | 0.00% | – |
| Q1 2019 | $280,000 | +104.4% | 33,886 | +21.4% | 0.00% | – |
| Q4 2018 | $137,000 | -27.5% | 27,922 | +102.8% | 0.00% | – |
| Q2 2018 | $189,000 | – | 13,770 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| CAXTON CORP | 1,142,360 | $7,745,000 | 4.83% |
| RA Capital Management | 10,874,613 | $73,730,000 | 1.03% |
| Mesirow Financial Investment Management, Inc. | 43,431 | $294,462,000 | 0.93% |
| Parkman Healthcare Partners LLC | 272,445 | $1,847,000 | 0.47% |
| Samsara BioCapital, LLC | 601,162 | $4,076,000 | 0.41% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 102,198 | $693,000 | 0.40% |
| Eventide Asset Management | 3,450,000 | $23,391,000 | 0.36% |
| Orbimed Advisors | 5,465,030 | $37,053,000 | 0.32% |
| Vivo Capital, LLC | 786,883 | $5,335,000 | 0.24% |
| Knights of Columbus Asset Advisors LLC | 169,429 | $1,149,000 | 0.12% |